Cargando…
Neoadjuvant immune checkpoint inhibition in the management of glioblastoma: Exploring a new frontier
Brain tumors are one of the leading causes of cancer related death in both the adult and pediatric patient population. Gliomas represent a cohort of brain tumors derived from glial cell lineages which include astrocytomas, oligodendrogliomas and glioblastomas (GBMs). These tumors are known to grow a...
Autores principales: | Frederico, Stephen C., Darling, Corbin, Bielanin, John P., Dubinsky, Alexandra C., Zhang, Xiaoran, Hadjipanayis, Constantinos G., Kohanbash, Gary |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9981631/ https://www.ncbi.nlm.nih.gov/pubmed/36875096 http://dx.doi.org/10.3389/fimmu.2023.1057567 |
Ejemplares similares
-
Pre-clinical models for evaluating glioma targeted immunotherapies
por: Frederico, Stephen C., et al.
Publicado: (2023) -
TIGIT and PD-1 Immune Checkpoint Pathways Are Associated With Patient Outcome and Anti-Tumor Immunity in Glioblastoma
por: Raphael, Itay, et al.
Publicado: (2021) -
Treatment Progress of Immune Checkpoint Blockade Therapy for Glioblastoma
por: Zhang, Na, et al.
Publicado: (2020) -
Glioblastoma Immunotherapy Targeting the Innate Immune Checkpoint CD47-SIRPα Axis
por: Hu, Jinyang, et al.
Publicado: (2020) -
Fatty Acid Metabolic Signaling Pathway Alternation Predict Prognosis of Immune Checkpoint Inhibitors in Glioblastoma
por: Liu, Rongrong, et al.
Publicado: (2022)